BACKGROUND: Epithelial ovarian cancer continues to challenge clinicians. There is no accepted method of screening for ovarian cancer, and most patients present with advanced disease. In spite of advances in surgery and chemotherapy, survival continues to be poor. METHODS: The data, comprising the ovarian cancer caseloads of 940 hospitals, are from the National Cancer Data Base. The 15,254 patients, diagnosed in 1988 or 1993, had no prior cancer diagnosis. RESULTS: Data quality had improved by 1993; 89.4% of the records included American Joint Committee on Cancer (AJCC) staging information in 1993, compared with 67.9% in 1988. Borderline epithelial tumors and germ cell tumors were most commonly found in younger women and were more likely to be diagnosed at Stage I. The percentage of women with carcinoma treated only with surgery increased substantially by 1993. Relative survival decreased with increasing tumor stage or grade. Five-year survival was considerably lower for women with carcinoma (38%) than for women with either borderline carcinoma (95%) or germ cell tumors (86%). The addition of chemotherapy to the treatment of Stage I carcinoma did not improve outcome, nor was dramatic improvement in survival brought about by the addition of chemotherapy to the treatment of Stage II and III low grade disease. Chemotherapy was beneficial to patients with Stage II or III disease, Grade 3 or 4, and Stage IV disease. CONCLUSIONS: Most women with epithelial ovarian cancers continue to present with advanced disease. No improvements in early detection were apparent in the reference years studied. The benefits of the addition of chemotherapy to the treatment of this disease were most obvious in patients with Stage II and III disease, Grade 3 or 4, and those with Stage IV disease. These benefits were less clear in early stage disease. However, there continues to be significant room for improvement in the diagnosis and treatment of this disease.
BACKGROUND:Epithelial ovarian cancer continues to challenge clinicians. There is no accepted method of screening for ovarian cancer, and most patients present with advanced disease. In spite of advances in surgery and chemotherapy, survival continues to be poor. METHODS: The data, comprising the ovarian cancer caseloads of 940 hospitals, are from the National Cancer Data Base. The 15,254 patients, diagnosed in 1988 or 1993, had no prior cancer diagnosis. RESULTS: Data quality had improved by 1993; 89.4% of the records included American Joint Committee on Cancer (AJCC) staging information in 1993, compared with 67.9% in 1988. Borderline epithelial tumors and germ cell tumors were most commonly found in younger women and were more likely to be diagnosed at Stage I. The percentage of women with carcinoma treated only with surgery increased substantially by 1993. Relative survival decreased with increasing tumor stage or grade. Five-year survival was considerably lower for women with carcinoma (38%) than for women with either borderline carcinoma (95%) or germ cell tumors (86%). The addition of chemotherapy to the treatment of Stage I carcinoma did not improve outcome, nor was dramatic improvement in survival brought about by the addition of chemotherapy to the treatment of Stage II and III low grade disease. Chemotherapy was beneficial to patients with Stage II or III disease, Grade 3 or 4, and Stage IV disease. CONCLUSIONS: Most women with epithelial ovarian cancers continue to present with advanced disease. No improvements in early detection were apparent in the reference years studied. The benefits of the addition of chemotherapy to the treatment of this disease were most obvious in patients with Stage II and III disease, Grade 3 or 4, and those with Stage IV disease. These benefits were less clear in early stage disease. However, there continues to be significant room for improvement in the diagnosis and treatment of this disease.
Authors: William A Cliby; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; Robert E Bristow Journal: Gynecol Oncol Date: 2014-10-29 Impact factor: 5.482